Solara Active Pharma Sciences informed the stock exchanges on May 15, 2026, that its Board of Directors met on the same date and approved revisions to certain company policies, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key Policy Updates Approved by the Board

The Board meeting resulted in two significant governance-related decisions, both aimed at aligning the company's internal framework with applicable regulatory standards. The details of the approved matters are outlined below:

Board Evaluation Policy Adoption

The Board formally adopted the Board Evaluation Policy in compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and any amendments thereto. The policy has been made available on the company's website under the investor relations section covering policies and guidelines.

Whistle Blower Policy Amendment

The Whistle Blower Policy was amended to incorporate necessary revisions and modifications in line with applicable requirements. The updated policy is also accessible on the company's official website at the investor relations section. The intimation was signed by Pooja Jaya Kumar, Company Secretary and Compliance Officer, on May 15, 2026.

The Board of Directors of Solara Active Pharma Sciences Limited, at their meeting held on May 15, 2026, approved the re-appointment of both the Internal Auditors and Cost Auditors of the company for the financial year 2026-27. The decision was disclosed to the stock exchanges in accordance with Regulation 30 read with Para A, Part-A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI Master Circular dated January 30, 2026.

Auditor Re-Appointments at a Glance

The following table summarises the key details of both re-appointments as disclosed by the company:

Profile of the Internal Auditor

M/s. Grant Thornton Bharat LLP is described as one of the leading professional service firms offering business advisory services for foreign and Indian companies. The firm works with businesses and government entities across industries and sectors, providing a broad range of services including assurance, consulting, tax, risk, regulatory, finance, and digital and technology transformation services.

Profile of the Cost Auditor

Mr. K. Suryanarayanan is a Fellow member of the Institute of Cost Accountants of India with more than two decades of experience in Finance, Accounts, MIS, Costing, and Taxation. He has served as a faculty member of the Institute of Cost Accountants of India and other management institutes, handling Cost Accounting Standards and Cost Audit for final students of CA and CMA programmes. He is also a visiting faculty to government and non-government entities and has conducted special audits and desk reviews under the provisions of Indirect Tax for reputed multinationals. Additionally, he has handled various assignments connected to Insurance and Transfer Pricing.

Regulatory Compliance

The re-appointments were made in compliance with the applicable provisions of the SEBI Listing Regulations. The company confirmed that there are no relationships between the re-appointed auditors and the directors of the company. The disclosure was signed by Pooja Jaya Kumar, Company Secretary and Compliance Officer (Membership No.: A57415), on behalf of Solara Active Pharma Sciences Limited.